Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag(Chan Zuckerberg Biohub San Francisco), K. B. Nolop(Plexxikon (United States)), Keith T. Flaherty(Cancer Research Center), Raman Iyer(Kingsley House), Michael Stumm(University of Toronto), James Tsai(Plexxikon (United States)), Richard J. Lee(La Roche College), Kam Y. J. Zhang(RIKEN Center for Biosystems Dynamics Research), Brian Higgins(La Roche College), Wayne Spevak(Plexxikon (United States)), Peter Hirth(Plexxikon (United States)), Grant A. McArthur(The University of Melbourne), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Ben Powell(Plexxikon (United States)), Bernice H. Wong(Plexxikon (United States)), Joseph Schlessinger(Yale University), Rafe Shellooe(Plexxikon (United States)), Elizabeth A. Burton(Children's Hospital of Philadelphia), Katherine L. Nathanson(Translational Therapeutics (United States)), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Astrid Koehler(Kingsley House), Antoni Ribas(University of California, Los Angeles), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Brian L. West(The University of Queensland), Garson Tsang(Plexxikon (United States)), Kurt D’Andrea(University of Pennsylvania), Ying Zhang(Sun Yat-sen University), Chao Zhang(University of Southern California), Hanna Cho(Yonsei University), Fei Su(Bengbu Medical College), Xiaowei Xu(University of Pennsylvania), Hoa Nguyen(Plexxikon (United States)), Jiazhong Zhang(Plexxikon (United States)), Prabha N. Ibrahim(Plexxikon (United States)), Dean R. Artis(Plexxikon (United States)), Paul Lin, Adhirai Marimuthu(Plexxikon (United States)), Gaston Habets(Plexxikon (United States)), Joseph F. Grippo(Inflarx (Germany)), Kevin B. Kim(The University of Texas MD Anderson Cancer Center)
Nature
September 1, 2010
Cited by 1,822


Related Papers